Feasibility of endoscopic ultrasound-guided OncoGel (ReGel/Paclitaxel) injection into the pancreas in pigs

Endoscopy

Volumn 37, Issue 11, 2005, Pages 1140-1142

  Linghu, E ^a   Matthes, K ^b   Mino Kenudson, M ^b   Brugge, W R ^b  

^a Chinese Military Postgraduate Medical College   (China)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOGEL; PACLITAXEL; REGEL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANOREXIA; ARTICLE; CONTROLLED STUDY; DRUG EXTRAVASATION; DRUG FORMULATION; DRUG TISSUE LEVEL; ENDOSCOPIC ECHOGRAPHY; FEASIBILITY STUDY; FEVER; GENERAL ANESTHESIA; HISTOPATHOLOGY; MALE; NEEDLE BIOPSY; NONHUMAN; PANCREAS CANCER; PANCREAS NECROSIS; PANCREATITIS; PRIORITY JOURNAL; SCLEROSIS; SEDATION; SWINE; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS; ENDOSONOGRAPHY; FEASIBILITY STUDIES; INJECTIONS, INTRALESIONAL; MALE; PACLITAXEL; PANCREAS; SWINE; TREATMENT OUTCOME;

EID: 27644591376     PISSN: 0013726X     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-870224     Document Type: Article

References (10)

1. Kozuch P, Petryk M, Evans A et al. Therapy for regionally unresectable pancreatic cancer. Surg Clin North Am 2001; 81: 691-697
2. Bhutani MS. Endoscopic ultrasound-guided antitumor therapy. Endoscopy 2003; 35: S54-S56
3. Chang KJ, Nguyen PT, Thompson JA et al. Phase I clinical trial of allogeneic mixed lymphocyte culture (cytoimplant) delivered by endoscopic ultrasound-guided fine-needle injection in patients with advanced pancreatic carcinoma. Cancer 2000; 88: 1325-1335
4. Jeong B, Bae YH, Lee DS et al. Biodegradable block copolymers as injectable drug-delivery systems. Nature 1997; 388: 860-862
5. Zentner GM, Rathi R, Shih C et al. Biodegradable block copolymers for delivery of proteins and water-insoluble drugs.J Control Release 2001; 72: 203-215
6. Takekuni K, Sakon M, Kishimoto S et al. A patient with unresectable cancer of pancreas head, effectively treated by a local injection of the mixture of OK-432, fibrinogen and thrombin [in Japanese, English abstract]. Gan To Kagaku Ryoho 1996; 23: 1621-1623
7. Mulvihill S, Warren R, Venook A et al. Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial. Gene Ther 2001; 8: 308-315
8. Cohen EE, Rudin CM. ONYX-015. Onyx Pharmaceuticals. Curr Opin Investig Drugs 2001; 2: 1770-1775
9. Makower D, Rozenblit A, Kaufman H et al. Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studies. Clin Cancer Res 2003; 9: 693-702
10. Hecht JR, Bedford R, Abbruzzese JL et al. A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin Cancer Res 2003; 9: 555-561